High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D, Hughes BGM, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dréno B, Migden MR, Hauschild A, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A.
Rischin D, et al. Among authors: okoye e.
J Immunother Cancer. 2024 Mar 11;12(3):e008325. doi: 10.1136/jitc-2023-008325.
J Immunother Cancer. 2024.
PMID: 38471711
Free PMC article.
Clinical Trial.